Specialty drugmaker Swedish Orphan Biovitrum (Sobi) has given the cold shoulder to a potential buyer, that may or may not be Pfizer, who was not giving it the kind of financial appreciation that it believes it deserves. But given the frenetic M&A market, an analyst says it is probably just a matter of time before someone snaps up the orphan drugmaker.
Sobi has stepped away from the bargaining table without completing a rumored $5 billion deal to sell the company.
Deal-hungry Shire hasn't snagged any new marketed drugs since bagging NPS Pharma in a deal it announced in January. But the rumor mill is churning again, and word has it it's set its sights on Actelion.
OPKO Health is snatching up Bio-Reference Laboratories for $1.47 billion to get its hands on the company's genetic sequencing technology and harness Bio-Reference's lab capabilities for drug development.
Endo hasn't quite wrapped up its $8 billion deal for generics maker Par Pharmaceutical, recently agreeing to a loan package to speed things along. Now, the drugmaker is hoping to move one step closer to the finish line by launching a $1.75 billion stock sale.
Teva already has a 1.8% stake in deal target Mylan--a share that prompted Mylan Chairman Robert Coury to accuse it on Monday of breaching U.S. antitrust laws. But the Israeli drugmaker's response may be to pad that stake even further.
Pozen has had its share of woes in recent months: Manufacturing problems at its contract supplier tanked new drug applications twice in a row, and Big Pharma partner Sanofi bailed on their development deal for the new-and-improved aspirins.
Lately, Perrigo's shown it would rather be the acquirer than the acquired--and it continued down that path Tuesday.
Clock's ticking, Teva, as far as deal target Mylan's concerned. The Israeli drugmaker needs to either "stop playing games" and turn its $40 billion approach into a formal bid--or walk.
Juno Therapeutics, at work on immune system-harnessing cancer treatments, bought up a small Massachusetts biotech to further flesh out its arsenal of technologies, picking up a new discovery platform as it races toward late-stage trials.